Kringle Pharma, Inc. stock analysis
Want to see JP:4884 full AI Analyst Report?
Kringle Pharma, Inc. (4884) Stock Price & Analysis
4884 Stock Chart & Stats
- Day’s Range
- JPY 509.00 - JPY 584.00
- 52-Week Range
- JPY 287.00 - JPY 741.00
- Previous Close
- JPY 519.00
- Volume
- N/A
- Average Volume (3M)
- 431.36K
- Market Cap
- JPY 4.79B
- Enterprise Value
- JPY 1.08B
- Total Cash (Recent Filing)
- JPY 1.70B
- Total Debt (Recent Filing)
- JPY 0
- Price to Earnings (P/E)
- ―
- Beta
- 0.59
- Next Earnings
- Feb 05, 2027 (Est.)
- EPS Estimate
- N/A
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- N/A
Bulls Say, Bears Say
Bulls Say
High Gross Margin
The approximately 84% gross margin indicates strong economics on revenue already generated and leaves meaningful room to cover operating costs if scale improves. While insufficient to offset current expenses today, this margin profile could support future profitability if revenue becomes more consistent.
Revenue Rebound
The latest revenue rebound demonstrates that Kringle Pharma can generate materially higher sales than its depressed 2025 base. Sustaining or building on this recovery would improve operating leverage, strengthen commercial traction, and provide a larger base from which to absorb fixed research and corporate costs.
Zero Debt
A debt-free balance sheet reduces refinancing exposure and eliminates interest-rate pressure that could otherwise compound the company’s operating losses. This gives management greater financial flexibility to allocate available capital toward development and operations without servicing a lender-funded capital structure.
Bears Say
Persistent Net Losses
Persistent, substantial net losses show that the current business has not yet converted its high gross margin into a sustainable earnings model. Continued losses can require repeated external funding, limit strategic flexibility, and make future profitability dependent on significant cost improvement or further revenue expansion.
Operating Cash Burn
Deeply negative operating cash flow indicates that ongoing activities consume cash rather than fund themselves. This weakens financial resilience over the next several quarters and raises the importance of maintaining funding access while the company works to develop products and reach a self-sustaining operating model.
Eroding Equity Base
The sustained decline in equity reflects the cumulative effect of ongoing losses and reduces the capital cushion available to support future operations. Even without debt, continued equity erosion can increase dependence on new capital and weaken the company’s ability to absorb delays in revenue or product development.
Kringle Pharma, Inc. News
Kringle Pharma Launches Additional Phase 3 Trial of Oremepermin Alfa in Acute Spinal Cord Injury
Kringle Pharma, Inc. ( ($JP:4884) ) has shared an announcement. Kringle Pharma has launched an additional Phase 3 trial in Japan to evaluate oremepermin alfa, a recombinant human hepatocyte growth
Kringle Pharma’s Phase 3 Study on KP-100LI: A Potential Game-Changer for Vocal Fold Scar Treatment
Kringle Pharma, Inc. (($JP:4884)) announced an update on their ongoing clinical study. Kringle Pharma, Inc. is conducting a Phase 3 clinical study titled ‘A Multicenter, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group Confirmatory
4884 FAQ
What was Kringle Pharma, Inc.’s price range in the past 12 months?
What is Kringle Pharma, Inc.’s market cap?
When is Kringle Pharma, Inc.’s upcoming earnings report date?
How were Kringle Pharma, Inc.’s earnings last quarter?
Is Kringle Pharma, Inc. overvalued?
Does Kringle Pharma, Inc. pay dividends?
What is Kringle Pharma, Inc.’s EPS estimate?
How many shares outstanding does Kringle Pharma, Inc. have?
What happened to Kringle Pharma, Inc.’s price movement after its last earnings report?
Which hedge fund is a major shareholder of Kringle Pharma, Inc.?
What is the TipRanks Smart Score and how is it calculated?
Company Description
Kringle Pharma, Inc.
Kringle Pharma, Inc. specializes in the innovation, production, and distribution of hepatocyte growth factor (HGF) protein-based therapeutics aimed at regenerative medicine. The company's cutting-edge HGF solutions are designed to address serious medical conditions including acute spinal cord injury, amyotrophic lateral sclerosis, vocal fold scars, and acute kidney injury. Founded in 2001, Kringle Pharma operates from its base in Ibaraki, Japan.
- Sector
- General
- Industry
- Biotechnology
- CEO
- Kiichi Adachi
- Employees
- 17
- Website
- www.kringle-pharma.com
- Address
- Nakanoshima Qross Research & Development Center, Kita, 530-0005, JP
Kringle Pharma, Inc. (4884) Earnings & Revenues
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 14 | 6 | 2 |
| Technical Analysis | 3 | 6 | 1 |
| Moving Averages | 11 | 0 | 1 |










